In this paper we describe methods for addressing multiplicity issues arising in the analysis of clinical trials with multiple endpoints and/or multiple dose levels. Efficient "gatekeeping strategies" for multiplicity problems of this kind are developed. One family of hypotheses (comprised of the primary objectives) is treated as a "gatekeeper," and the other family or families (comprised of secondary and tertiary objectives) are tested only if one or more gatekeeper hypotheses have been rejected. We discuss methods for constructing gatekeeping testing procedures using weighted Bonferroni tests, weighted Simes tests, and weighted resampling-based tests, all within a closed testing framework. The new strategies are illustrated using an example from a clinical trial with co-primary endpoints, and using an example from a dose-finding study with multiple endpoints. Power comparisons with competing methods show the gatekeeping methods are more powerful when the primary objective of the trial must be met.
Summary
In this paper we describe methods for addressing multiplicity issues arising in the analysis of clinical trials with multiple endpoints and/or multiple dose levels. Efficient "gatekeeping strategies" for multiplicity problems of this kind are developed. One family of hypotheses (comprised of the primary objectives) is treated as a "gatekeeper," and the other family or families (comprised of secondary and tertiary objectives) are tested only if one or more gatekeeper hypotheses have been rejected. We discuss methods for constructing gatekeeping testing procedures using weighted Bonferroni tests, weighted Simes tests, and weighted resampling-based tests, all within a closed testing framework. The new strategies are illustrated using an example from a clinical trial with co-primary endpoints, and using an example from a dose-finding study with multiple endpoints. Power comparisons with competing methods show the gatekeeping methods are more powerful when the primary objective of the trial must be met.
Introduction
Hypotheses tested in clinical trials are commonly divided into primary and secondary. The primary hypothesis is related to the primary trial endpoint which describes the most important features of the disease under study. O'Neill [1] defines the primary endpoint as "a clinical endpoint that provides evidence sufficient to fully characterize clinically the effect of a treatment in a manner that would support a regulatory claim for the treatment." In many cases, the primary hypothesis test determines the overall conclusion from the trial. Secondary hypotheses also play an important role in characterizing the effects of the study drug. However, a significant improvement in a secondary endpoint in isolation is not generally considered as substantial evidence of therapeutic benefit.
The interpretation of a positive finding with respect to a secondary outcome variable depends heavily on its clinical importance. The following general types of secondary outcome variables are based on D'Agostino [2] :
Type I. Separate components of the primary trial objective. These may be very important secondary endpoints that are difficult to incorporate into the formal power calculation because the expected improvement is relatively small. All-cause mortality plays this role in a large number of trials including cardiovascular and critical care studies.
Type II. Endpoints that help interpret the primary findings. These endpoints are very helpful for understanding the big picture, e.g., understanding the benefits with respect to various aspects of the disease. The effect of osteoarthritis drugs is typically measured using pain and physical function indices; however, there are other important outcome variables such as patient global assessment and quality-of-life measures.
A similar classification of secondary endpoints is proposed in the guideline entitled "Points to consider on multiplicity issues in clinical trials" published by the Committee for Proprietary Medicinal Products (CPMP) [3] .
With this classification in mind, it is critically important to prospectively define not only the hypotheses of interest but also a decision rule that will be used to guide the decision-making process at study completion (Chi [4] ). The decision rule can have a flexible hierarchical structure with several data-driven clinical decision paths. The clinical statistician "translates" this decision rule into a statistical procedure that incorporates the interrelationships among the primary and secondary trial hypotheses.
Multiplicity problems arising in the context of primary and secondary trial hypotheses can be effectively dealt with using hierarchical testing procedures, also known as "gatekeeping procedures." Consider two families of outcome variables, e.g., primary variables that can lead to new regulatory claims (gatekeeper) and secondary variables that may become the basis for additional claims. The gatekeeper family is tested without an adjustment for the other family, and the second family is examined only if the gatekeeper has been successfully passed; see Bauer et al. [5] , Westfall and Krishen [6] , and Gong, Pinheiro and DeMets [7] .
Gatekeeping procedures proposed in the literature have been designed for the case when the gatekeeper family is passed only if all of the hypotheses in the family have been rejected, which we refer to as "serial" gatekeeping procedures. Serial procedures can be too restrictive; for example, the requirement to reject all primary trial hypotheses before performing the secondary analyses may be inappropriate when the co-primary endpoints can lead to separate regulatory claims. Similarly, the analysis of individual doses of an experimental drug in a dose-finding setting can be enhanced by using a hierarchical testing strategy, e.g., one examines the higher doses first and studies the lower doses if at least one of the higher doses (but not necessarily both) has shown a significant difference from the control.
Thus, while it is well known that one can proceed in serial fashion, it is apparently not known that gatekeeping tests also can be performed in "parallel" fashion, where one may proceed to the secondary family when at least one of the primary tests exhibits significance. The main contribution of this paper is the development of such parallel gatekeeping procedures.
An alternative to gatekeeping strategies is the prospective alpha allocation scheme (PAAS) proposed by Moyé [8] , in which the primary and secondary endpoints are tested simultaneously at levels less than the common 0.05 threshold, ensuring that the total threshold is still 0.05. This approach has been designed for the cases when the secondary endpoints may potentially provide the basis for a new regulatory claim. If the primary effects are truly null, the PAAS strategy is more powerful than a gatekeeping strategy. On the other hand, when some of the primary hypotheses are false, the power gains of gatekeeping strategies can be substantial, as we demonstrate in Section 6.
In this paper, we develop parallel gatekeeping methods using the powerful closed testing principle of Marcus et al. [9] . Section 2 introduces closed gatekeeping procedures based on the weighted version of the Bonferroni test. Section 3 discusses extensions based on the weighted Simes test and parametric resampling. The described gatekeeping strategies are illustrated in Sections 4 and 5 using two clinical trial examples, one with two co-primary endpoints and the other a dose-finding study. Section 6 compares the power of the various testing procedures.
Consider a family of null hypotheses H 1 , . . . , H m and assume that the hypotheses are grouped into two families, F 1 = {H 1 , . . . , H k } and F 2 = {H k+1 , . . . , H m }. The first family serves as a gatekeeper in the sense that F 1 is tested without an adjustment for F 2 and H k+1 , . . . , H m are examined only if the gatekeeper has been successfully passed. It will be assumed throughout the paper that F 1 is a parallel gatekeeper, i.e., H k+1 , . . . , H m can be tested if at least one hypothesis in F 1 has been rejected. In the clinical trial context, F 1 and F 2 can represent sets of the primary and secondary trial hypotheses, respectively. We are interested in constructing a testing strategy that controls the familywise error rate (FWE) with respect to both families of hypotheses in the strong sense (Hochberg and Tamhane [10] ).
To apply the closed testing principle to the problem of testing F 1 and F 2 , consider an arbitrary intersection hypothesis H in the closed family associated with H 1 , . . . , H m . Let p 1 , . . . , p m denote the raw p-values for H 1 , . . . , H m . Further, let p H denote the p-value associated with H, obtained from a test procedure whose size is no more than α when H is true. The closed testing principle states that an original hypothesis is rejected provided all of the p-values associated with the intersection hypotheses containing it are significant. Therefore, the adjusted p-value associated with the hypothesis H i equals p i = max H∈H i p H , where H i denotes the set of all intersection hypotheses that contain H i . The closed testing procedure rejects H i when p i ≤ α, and strongly controls the FWE at the α level, over the combined family (H 1 , . . . , H m ). Note that the adjusted p-value depends on the test procedure chosen to test H; the key to our gatekeeping procedures is the particular choice of tests for each H, as we now describe.
Parallel gatekeeping procedures can be defined using weighted Bonferroni tests for the intersection hypotheses. Select an intersection hypothesis H and consider a set of m weights
Here δ i (H) = 1 if H ∈ H i and 0 otherwise. The weighted Bonferroni p-value associated with H is given by
, and H is rejected if p H ≤ α. By the Bonferroni inequality, the size of this test is no greater than α. Therefore, the resulting closed testing procedure for the original hypotheses controls the FWE in the strong sense for any set of weight vectors.
The PAAS procedure fits with the current framework as follows: Suppose the weights are fixed for all hypotheses (v i (H) ≡ v i ) and that H is tested using p
is equivalent to the closed testing procedure using p-values p (P AAS) H for the intersection hypotheses. Viewed as a closed testing procedure, one can see that (i) the weights for the PAAS procedure are identical for all intersections, and (ii) the PAAS method uses extremely conservative tests for some of the intersection hypotheses; for example, the levels of the singletons are v i α, potentially much less than α. More power can be obtained using more powerful tests for the intersections; this is the essential contribution of Holm [19] .
In what follows we describe an FWE-controlling closed procedure for testing F 1 and F 2 that meets the following parallel gatekeeping criteria: The following algorithm shows how to choose the weight vectors to satisfy Conditions 1 and 2. Suppose that w 1 , . . . , w m represent the relative importance of the null hypotheses in F 1 and F 2 with w 1 +. . .+w k = 1 and w k+1 +. . .+w m = 1. For example, w 1 may be set to 0.8 if H 1 corresponds to the most important primary trial endpoint and 0.2 may be distributed evenly across the remaining gatekeeper hypotheses associated with the less important outcome variables. Using the w i , we define weights v i (H) to use in a Bonferroni test of hypothesis H. Every hypothesis H will be tested using a potentially different set of weights (v 1 (H), . . . , v m (H)).
Algorithm 1. Selecting the weights for the parallel Bonferroni gatekeeping procedure
Select a hypothesis in the closed family and denote it by H. Consider the following three mutually exclusive cases:
. . , k, and
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For example, suppose there are two primary and two secondary hypotheses, with equal weights assumed for all tests. There are 2 4 − 1 = 15 intersection hypotheses H. Table 1 shows the weights v i (H) that are used for each test. The parallel gatekeeping procedure simply uses weighted Bonferroni tests for every intersection, with weights as shown.
It is also instructive to compare the proposed weighting scheme with the weighting scheme underlying serial gatekeeping procedures discussed by Westfall and Krishen [6] . Westfall and Krishen showed that serial gatekeeping strategies can be set up by sequentially carrying out two weighted Holm tests [19] , i.e., by using the following algorithm for defining weight vectors in the closed test for H 1 , . . . , H m : Algorithm 2. The weighting scheme for the serial Bonferroni gatekeeping procedure Select a hypothesis in the closed family and denote it by H. Consider the following two mutually exclusive cases:
One can verify that this choice of the weight vectors ensures that the adjusted p-values associated with H k+1 , . . . , H m are greater than the maximum of p 1 , . . . , p k . In other words, one can test the hypotheses in F 2 only if all hypotheses in F 1 have been rejected. To construct a parallel gatekeeping procedure, one needs to modify the serial weighting scheme by assigning smaller weights to H 1 , . . . , H k when H contains some but not all gatekeeper hypotheses. For example, assume that H is the intersection of H 1 , . . . , H k−1 and H k+1 , . . . , H m but does not contain H k . The weight vector associated with the serial gatekeeping approach (see Algorithm 2) is
It is important to note that weights for H 1 , . . . , H k−1 are defined in such a way that they add up to 1. This immediately implies that the weights assigned to the hypotheses in F 2 are set to zero. To modify the serial weighting scheme, note that the weights associated with the gatekeeper hypotheses contained in H do not add up to 1 in this scenario, i.e., w 1 + . . . + w k−1 < 1. This gives us an ability to incorporate the secondary p-values into the decision rule. Specifically, the gatekeeper hypotheses will receive the pre-specified weights, i.e., w 1 , . . . , w k−1 , and the remainder (i.e., 1 − k−1 j=1 w j ) will be distributed among the secondary hypotheses according to their importance, i.e., the following weight vector will be constructed:
An important property of the parallel weighting scheme defined in Algorithm 1 is that the adjusted p-values associated with the gatekeeper hypotheses are given by p i = p i /w i , i = 1, . . . , k. This implies that the hypotheses in F 1 are tested using the weighted Bonferroni tests that take into account the relative importance of the hypotheses. As a result, the gatekeeper hypotheses will be rejected whenever their Bonferroni-adjusted p-values are significant regardless of the values of p k+1 , . . . , p m and thus Condition 1 is satisfied. Further, it is easy to demonstrate that the adjusted p-values p k+1 , . . . , p m are greater than the minimum of p 1 , . . . , p k . The closed testing procedure based on the weighting scheme in Algorithm 1 satisfies Condition 2 and therefore it presents a valid parallel gatekeeping procedure.
Gatekeeping procedures based on Simes and resampling tests
The gatekeeping procedure introduced in the previous section is based on the Bonferroni test and thus ignores the correlation among the individual test statistics. It is troubling that (i) Bonferroni-based tests are conservative for large correlation and (ii) Bonferroni-based tests may all be insignificant even when all unadjusted p-values are significant. Resampling-based procedures [11] can alleviate problem (i); while use of Simes [12] test can alleviate problem (ii).
Simes proposed the following test for an intersection hypothesis H in the closed family. Let t denote the number of elemental hypotheses contained in H and p (1)H ≤ p (2)H ≤ · · · ≤ p (t)H denote the ordered p-values for the elemental hypotheses. The Simes p-value is then given by p H = t min 1≤j≤t p (j)H /j. Exact Type I error control was proven under independence by Simes [12] and conservative Type I error control was established under positive dependency among p-values by Sarkar [13] . This test always produces p-values as small or smaller than the Bonferroni test, for which p H = tp (1)H . The Simes test is popular because of its improved power and because of its close connection with procedures that control the false discovery rate (Benjamini and Hochberg [14] ).
Since our methodology uses weighted Bonferroni tests, we use the weighted Simes test proposed by Benjamini and Hochberg [15] . Consider an intersection hypothesis H and a weight vector v i (H), i = 1, . . . , m. Let t and p (1)H , . . . , p (t)H be defined as above and let v (1)H , . . . , v (t)H denote the weights corresponding to the ordered p-values. The weighted Simes p-value is equal to
Proof of Type I error control for this procedure under positive regression dependency is given by Kling and Benjamini [16] , thus any closed testing procedure that uses such tests for the intersection hypotheses controls the FWE strongly under the same conditions.
Resampling-based p-values for H 1 , . . . , H m can be obtained by using parametric resampling. The resulting adjusted p-values are useful (i) to assess robustness of the Simes-based and Bonferroni-based tests to correlation that may be typical for clinical trials, and (ii) to provide alternative large-sample multiplicity-adjusted p-values that directly incorporate correlation. To obtain the parametric resampling-based pvalues, consider an intersection hypothesis H and let p H denote the observed p-value (weighted Bonferroni or weighted Simes) for H. Assuming the usual multivariate normal MANOVA assumptions for our data, with true correlation matrix ρ, the "true p-value" is p H (ρ) = P (P H ≤ p H |ρ). An approximate p-value is obtained as the plug-in estimator p H (ρ), which can easily be simulated as follows (see Westfall and Young [11] , p. 122-125, and Westfall et. al [17] , p.130-131, for details):
1. Given a consistent estimate of ρ (denoted byρ), generate B sets of n independent identically distributed N (0,ρ) vectors, where n is the combined sample size and B is the number of simulations.
2. Compute a vector of raw p-values for H 1 , . . . , H m from each simulated data set. Calculate the combined Bonferroni or Simes p-value for each intersection hypothesis in the closed family using the weight vectors defined by Algorithm 1. The obtained p-value for H from the ith simulated data set will be denoted by p * H (i). 3. The resampling-based p-value for H is equal tô
where δ(·) is the indicator function.
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A clinical trial with co-primary endpoints
Consider a clinical trial in patients with acute respiratory distress syndrome (ARDS).
The trial is conducted to compare one dose of a new drug to placebo. The therapeutic benefits of experimental treatments in ARDS trials are commonly measured using the number of days alive and off mechanical ventilation during a 28-day study period and 28-day all-cause mortality rate (see [18] for a detailed description of a recent trial in ARDS patients). Let H 1 and H 2 denote the null hypotheses of no treatment effect with respect to the number of ventilator-free days and 28-day all-cause mortality. It typically takes fewer patients to detect a clinically relevant improvement in the number of ventilator-free days compared to 28-day mortality. For this reason, the number of ventilator-free days often serves as the primary endpoint in ARDS trials. However, either of these two endpoints can be used to make regulatory claims. Additionally, there is interest in including information about the drug effects on the number of days the patients were out of the intensive care unit (ICU-free days) and general quality of life in the product label. Denote the secondary hypotheses associated with these secondary endpoints by H 3 and H 4 . We wish to develop a parallel gatekeeping procedure that will test the secondary hypotheses only if at least one primary hypothesis has been rejected. Suppose that the weights for the two gatekeeper hypotheses are given by w 1 = 0.9 and w 2 = 0.1 and the secondary hypotheses are equally weighted, i.e., w 3 = w 4 = 0.5. To define the adjusted p-values for H 1 , . . . , H 4 , consider the closed family associated with the four hypotheses of interest. The closed family includes 15 intersection hypotheses. It is convenient to adopt the following binary representation of the intersection hypotheses. If an intersection hypothesis equals H 1 , it will be denoted by H 1000 . Similarly,
The decision matrix in Table 2 serves as a useful tool that facilitates the computation of p-values for each intersection hypothesis in the closed family and also the adjusted p-values associated with the four original hypotheses. The p-values shown in Table  2 are based on the weighted Bonferroni rule. To implement the Simes gatekeeping procedure, one needs to test the individual intersection hypotheses using the weighted Simes test introduced in Section 3.
Each row in Table 2 corresponds to an intersection hypothesis. The p-values associated with the intersection hypotheses are defined using the weighting scheme defined in Algorithm 1. The adjusted p-value for H 1 , H 2 , H 3 and H 4 equals the largest p-value in the corresponding column, i.e., Inferences with respect to H 1 , H 2 , H 3 and H 4 are performed by comparing these adjusted p-values with the pre-specified α.
As an illustration, Table 3 presents the raw and adjusted p-values produced by the Bonferroni and Simes gatekeeping procedures under three scenarios. Table 3 shows that all four Bonferroni-and Simes-adjusted p-values are significant at the 0.05 level under the assumptions of Scenario 1. This means that the gatekeeping procedures have rejected both gatekeeper hypotheses and continued to test the secondary hypotheses, both of which were also rejected. It is worth noting that the adjusted pvalues for the mortality endpoint are considerably larger than the corresponding raw p-value. This is caused by the fact that this endpoint was considered less important than the number of ventilator-free days and was assigned a small weight (w 2 = 0.1). Further, the adjusted p-values for the quality of life assessment are also larger than the corresponding raw p-value. This happened because the gatekeeping procedures adjusted the raw p-value upward to make it consistent with the p-value associated with the more important gatekeeper hypothesis. In general, the amount by which secondary p-values are adjusted upward is determined largely by the magnitude of raw p-values associated with the gatekeeper hypotheses. Note also that the weighted Simes test always produces p-values that are as small or smaller than those of the weighted Bonferroni test. As a result, the Simes gatekeeping procedure produced adjusted p-values that are uniformly smaller than the corresponding Bonferroni-adjusted p-values, without sacrificing Type I error control.
Considering Scenario 2, we see that an increase in the raw p-value for the number of ventilator-free days did not affect the magnitude of the Bonferroni-adjusted p-value for mortality. This highlights the fact that the gatekeeper hypotheses are tested independently of each other when the Bonferroni gatekeeping procedure is used. Since both gatekeeping procedures have rejected the mortality hypothesis, the secondary analyses were undertaken and, as a result, the secondary hypothesis with the highly significant p-value was rejected. Again, the adjusted p-value for the quality of life assessment is substantially larger than the raw one. The magnitude of the upward adjustment simply reflects the fact that the more important gatekeeper null hypothesis is likely to be true and thus the Bonferroni and Simes procedures need more evidence against this secondary hypothesis to reject it.
Scenario 3 illustrates an important property of the Simes gatekeeping procedure. This procedure is known to reject all null hypotheses whenever all raw p-values are significant. Thus, the Simes gatekeeping procedure rejected all four null hypotheses in Scenario 3, whereas the Bonferroni procedures failed to detect significance with For more information, see http://www.multxpert.com/wiki/Gatekeeping Papers 11 respect to the number of ventilator-and ICU-free days.
5 A clinical trial with multiple endpoints and multiple doses Table 4 summarizes the results of a dose-finding study in patients with hypertension. The study was conducted to evaluate effects of low, medium and high doses of an investigational drug compared to placebo. The effects were measured by computing the reduction in systolic and diastolic blood pressure (SBP and DBP) measurements. The design of the testing strategy is of course done prior to data collection, but having the data visible helps to clarify what is done. In this study, it was felt a priori that (i) SBP is more indicative of true effect than DBP, and hence was placed higher in the hierarchy, and (ii) both the medium and high doses where considered equally important, and potentially equally powerful, while the lower dose was considered less likely to exhibit significance. Accordingly, the following four families of null hypotheses were considered: F 1 was comprised of the null hypotheses related to the High vs. Placebo and Medium vs. Placebo comparisons for SBP; F 2 was comprised of the null hypotheses related to the High vs. Placebo and Medium vs. Placebo comparisons for DBP; F 3 contained the null hypothesis for the Low vs. Placebo comparison for SBP; and F 4 contained the null hypothesis for the Low vs. Placebo comparison for DBP. The null hypotheses in F 1 and F 2 were tested in parallel fashion and were equally weighted within each family, reflecting equal importance of the high and medium doses. Table 5 displays the raw and adjusted p-values for the individual tests. The raw p-values were computed using the pooled-variance ANOVA two-sided contrast tests. The hierarchical strategy is better in this application than is the usual BonferroniHolm [19] or Simes-Hommel procedures [20] ; the adjusted p-values for the SimesHommel procedure are (in the vertical order of the table) 0.0348, 0.0032, 0.0573, 0.0080, 0.0430 and 0.0848, showing generally less significance. On the other hand, this example shows a case where the serial gatekeeping strategy would have worked better, since both hypotheses are significant in the first gate F 1 . However, had the p-values for the first gate not both been significant, the serial strategy would not have allowed continuation, as is allowed with our parallel testing procedure.
The resampling-based calculations shown in Table 5 used N =50,000,000, so that the Monte Carlo error is very small. We can see that, while resampling generally makes the adjusted p-values smaller, as is guaranteed for Bonferroni tests and has been proven recently for weighted Simes tests with positively dependent tests statistics [21] , the results are not much affected by correlation. Thus, as correlation has little effect on the adjusted p-values, we can recommend general use of the procedures without parametric resampling, except perhaps in borderline cases. (On the other hand, if non-normality is a great concern, then one should consider non-parametric resampling).
Power comparisons
A study was conducted to compare the performance of the Bonferroni, Simes and PAAS testing procedures in the case of four null hypotheses grouped into two families (e.g., two primary and two secondary hypotheses). It was assumed that the four individual null hypotheses are of the form The Bonferroni and Simes gatekeeping procedures were performed under the assumption that the null hypotheses were equally weighted within each family, i.e., w 1 = · · · = w 4 = 0.5. The adjusted p-values associated with these two gatekeeping procedures were computed as outlined in Sections 2 and 3. Two versions of the PAAS method were used. First, the four null hypotheses were weighted equally and the adjusted p-values were defined as p i = 4p i , i = 1, . . . , 4. Second, the two primary hypotheses received more weight and the PAAS-adjusted p-values were defined as follows:
Results for Bonferroni and Simes were obtained using simulation with 1,000,000 samples; all PAAS results were calculated analytically. Table 6 summarizes the results of the study. It shows that the PAAS procedures are more powerful than the gatekeeping procedures with respect to the secondary analyses when the primary null hypotheses are both true (µ 1 = µ 2 = 0), but that there are substantial power gains from using the Bonferroni and Simes gatekeeping procedures for testing the primary variables. In particular, if the regulatory mandate is to show a significance in the primary analysis, then the gatekeeping procedures show uniformly higher probability of meeting the regulatory mandate, as shown in the "F1" column.
It is important to emphasize that the PAAS procedures treat the four hypotheses in the two families as co-primary and test them simultaneously. This approach is justified when secondary endpoints may provide the basis for a new regulatory claim (Type I secondary endpoints by the D'Agostino classification [2] ). Under the gatekeeping strategies considered here, one does not test the secondary hypotheses unless at least one primary null hypothesis has been rejected. In other words, the gatekeeping approach assumes that the secondary findings will not lead to separate regulatory claims but can only provide supportive evidence for the claims based on the primary endpoints (Type II secondary endpoints by the D'Agostino classification).
As suggested by Westfall and Krishen [6] , the greatest gains in efficiency for the gatekeeping approach occur when the primary hypotheses have higher power; in our simulation we see that the gatekeeping procedures beat the PAAS procedures even for the secondary endpoints in these cases. An example of such a case is in dose-finding, where the higher doses are expected to exhibit higher power than the lower doses.
However, in fairness, it is important to note that for many disorders the secondary endpoints have greater power than the primary endpoints. Examples include oncology, where regulatory agencies may insist that sponsors demonstrate a benefit with respect to survival (time to death), although a key secondary endpoint, timeto-progressive-disease, generally has greater power. Another example is in depression, where regulators have insisted on the 17-item Hamilton Depression Scale total score as the primary outcome measure. The literature contains several subscales that have been shown to have greater power in discriminating between active drug and placebo [22] . So it may be true that under such scenarios the PAAS method would have greater power at detecting significant differences from a set of two primary and two secondary endpoints, for example. However, regulatory agencies generally would not consider the study as supporting efficacy unless the primary null hypothesis was rejected.
Discussion
This paper presents a framework for performing parallel gatekeeping inferences and outlines applications of gatekeeping procedures in clinical trials. Using the closed testing principle, we show how to construct powerful testing procedures that allow one to proceed to lower levels of the hierarchy when not all of the co-primary tests are significant. The benefits of the parallel gatekeeping approach are (i) regulatory acceptability in cases where a front gate of co-primary endpoints must be passed with at least one significance, and (ii) good power. The gatekeeping approach is most appropriate when the secondary analyses do not lead to separate regulatory claims but play a supportive role.
While the method is easiest to motivate and present in terms of Bonferroni-based gatekeeping procedure, we see power gains with the weighted Simes-based procedure and can therefore recommend it over the Bonferroni method. Furthermore, we find that the Simes gatekeeping procedure is relatively robust to correlation structure in a clinical example when correlations induced by multiple dose group comparisons and multiple endpoints, and therefore using that modification to accommodate correlation may not generally be needed. 
